Clinical trial · Observational
Real-World Outcomes in Relapsed/Refractory Multiple Myeloma Patients Treated, or Eligible for Treatment, With Idecabtagene Vicleucel
ABE-DESCART Study: Characterization and Outcomes of Patients With Relapsed and Refractory Multiple Myeloma Eligible for Treatment or Treated With Abecma© (Idecabtagene Vicleucel) in Real World Setting in France. A Database Analysis Based on the DESCAR-T Registry
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to describe demographic and disease characteristics, treatment patterns, and clinical outcomes in the real-world setting among participants in France with relapsed/refractory multiple myeloma (RRMM) who are eligible for treatment with, or have been treated with, idecabtagene vicleucel. This study will use both prospective and retrospective data from the DESCAR-T registry database.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Idecabtagene vicleucel | Drug | Idecabtagene Vicleucel | ALIAS |
| Not treated | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Treated with idecabtagene vicleucel
- interventionNames
- Drug: Idecabtagene vicleucel
- label
- Eligible for idecabtagene vicleucel
- description
- Eligible for idecabtagene vicleucel treatment but not treated
- interventionNames
- Other: Not treated
Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- 15 years
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Patients with RRMM registered in the DESCAR-T registry and eligible for treatment or treated with idecabtagene vicleucel Exclusion Criteria: * Not registered with the social security in France
References
Publications (0)
Data not yet available